Avoid the fibroid—Options in the management of uterine fibroids  by Huston, Mervyn et al.
lable at ScienceDirect
Taiwanese Journal of Obstetrics & Gynecology 55 (2016) 768Contents lists avaiTaiwanese Journal of Obstetrics & Gynecology
journal homepage: www.t jog-onl ine.comCorrespondenceAvoid the ﬁbroiddOptions in the management of uterine ﬁbroidsDear Editor
One of the age old debates in this specialty, the management of
uterine ﬁbroids, is under close scrutiny because never before has
there been so many treatment modalities available. As clinicians
it is incumbent that we fully explore and examine themerit of alter-
native therapies.
Traditionally medical management has been discredited owing
to limited efﬁcacy and concerns over side effects. Research in this
area which centers on gene therapy and receptor level target has
shown promise. Alternative medical regimens aim to coordinate
the hormonal activity of progesterone and estrogen, thus control-
ling uterine bleeding and cramps.
The levonorgestrel intrauterine system exerts its effect by
the local release of low concentration levonorgestrelda syn-
thetic progestational hormone. Analysis of its effect on women,
both with and without uterine ﬁbroids, has revealed it is effec-
tive in reducing abnormal uterine bleeding and shrinkage in the
volume of the uterus with a negligible effect on ﬁbroid volume
[1].
Gonadotropin releasing hormone agonists have a substantial ef-
fect on reducing the size of uterine ﬁbroids. Unfortunately, this
management option can be used for no more than 6 months, as
thereafter pseudo-effects of menopause are introduced. Discontin-
uation of gonadotropin releasing hormone treatment results in
regrowth [2].
Danazol, a synthetic androgen, suppresses the synthesis of
gonadotropin hormone and results in the lowering of estrogen
levels. This effect is reported to facilitate a modest reduction in
the volume of the uterine ﬁbroids and uterine bleeding tendency
[3].
Aromatase inhibitors such as letrozole have experimentally
shown the ability to reduce ﬁbroid size, by inhibiting the conver-
sion of androgen to estrogen [4]. Further study in this area is
ongoing.
Hysterectomy is often considered as the ﬁnal intervention and is
usually reserved for the management of symptomatic uterine ﬁ-
broids in postmenopausal women or where a malignant growth
is diagnosed. The alternative surgical intervention to consider is
myomectomy, where the uterine ﬁbroid is removed with the aim
of maintaining fertility. A number of methods can be employed in
carrying out myomectomies including heteroscopic, laporatic, and
laparoscopic approaches. Although this uterus-preservinghttp://dx.doi.org/10.1016/j.tjog.2016.08.001
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).procedure carries a distinct advantage, rates of recurrence as high
as 15% have been reported [5].
The vast expanse of patient presentation and variable patient
factors preclude the production of a rigid algorithm for manage-
ment; it must be tailored speciﬁcally to meet the needs of the indi-
vidual patient. It is important that we embrace new treatment
modalities and target their most efﬁcient and effective application
for the betterment of our patients health.
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